Catalyst Pharmaceutical Partners News (NASDAQ:CPRX)
| Latest Catalyst Pharmaceutical Partners News Headlines | | Date | Time | Source | | | 08/21/2008 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
CORAL GABLES, Fla., Aug 21 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today reported that animal data from a new study sponsored by scientists at the U.S. Department of Energy's Brookhaven National Laboratory appears to demonstrate that taking vigabatrin leads to rapid weight loss... More...>> |
| 08/15/2008 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
CORAL GABLES, Fla., Aug. 15 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today reported financial results for the second quarter and six months ended June 30, 2008.
"We continue to progress with our clinical development program for CPP-109," stated Patrick J. McEnany, Catalyst's Chief... More...>> |
| 06/30/2008 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphet
CORAL GABLES, Fla., June 30 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a biopharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction and obsessive compulsive disorders, today announced that it has begun... More...>> |
| 06/25/2008 | 11:23AM | PRNUS | Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index
CORAL GABLES, Fla., June 25 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) announced today that it is set to join the Russell Microcap(R) Index when Russell Investments reconstitutes its family of U.S. indexes on June 27, 2008, according to a preliminary list of additions posted on June... More...>> |
| 06/03/2008 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
CORAL GABLES, Fla., June 3 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction and obsessive compulsive disorders, today announced the filing of a shelf... More...>> |
| 05/16/2008 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners Reports First Quarter 2008 Financial Results
Frank Greenway, M.D. Joins Catalyst's Scientific Advisory Board
CORAL GABLES, Fla., May 16 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today reported financial results for the quarter ended March 31, 2008. The Company also announced the addition of Frank Greenway, M.D. to Catalyst's... More...>> |
| 03/26/2008 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
-- Currently enrolling patients in U.S. Phase II clinical trial for cocaine addiction
CORAL GABLES, Fla., March 26 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of... More...>> |
| 03/05/2008 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
Patrick Kenny, Former Senior Clinical Research Associate at Kendle International, Inc., Joins Catalyst
CORAL GABLES, Fla., March 5 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today announced the appointment of Patrick Kenny as Director - Corporate Clinical Compliance. In this capacity... More...>> |
| 01/25/2008 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addi
- Additional Clinical Trial Sites To Be Added -
CORAL GABLES, Fla., Jan. 25 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced that... More...>> |
| 12/07/2007 | 6:25AM | PRNUS | Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
- Study Demonstrates Statistically Significant Efficacy vs. Placebo -
CORAL GABLES, Fla., Dec. 7 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction... More...>> |
| 11/14/2007 | 5:51PM | PRNUS | Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results
CORAL GABLES, Fla., Nov. 14 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today reported financial results for the quarter ended September 30, 2007.
Third Quarter 2007 Results
For the quarter ended September 30, 2007, the Company reported a net loss of $734,347 or $0.06 loss per basic... More...>> |
| 10/30/2007 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners to Present at the Acumen Biofin 9th Annual Healthcare Conference
CORAL GABLES, Fla., Oct. 30 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) a biopharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced that Patrick J. McEnany, President and Chief Executive... More...>> |
| 08/29/2007 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners to Present at The Roth Capital Partners 2007 New York Conference
CORAL GABLES, Fla., Aug. 29 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) a specialty pharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction and obsessive compulsive disorders, today announced that Patrick... More...>> |
| 08/13/2007 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners Reports Second Quarter 2007 Financial Results
- Initiates U.S. Phase II Clinical Trial for Cocaine Dependence
CORAL GABLES, Fla., Aug. 13 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today reported financial results for the quarter ended June 30, 2007.
Second Quarter 2007 Results
For the quarter ended June 30, 2007, the Company... More...>> |
| 07/10/2007 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners, Inc. Initiates U.S. Phase II Clinical Trial of CPP-109 in Patients With Cocaine Dependence
CORAL GABLES, Fla., July 10 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) a specialty pharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced that it has initiated its randomized, double-blind... More...>> |
| 05/14/2007 | 6:33PM | PRNUS | Catalyst Pharmaceutical Partners Reports First Quarter 2007 Financial Results
Company Successfully Completes Bioequivalence Study
CORAL GABLES, Fla., May 14 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today reported financial results for the quarter ended March 31, 2007.
First Quarter 2007 Results
For the quarter ended March 31, 2007, the Company reported... More...>> |
| 05/09/2007 | 9:03AM | PRNUS | Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Compa
CORAL GABLES, Fla., May 9 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) announced today positive initial, top-line results from a bioequivalence study demonstrating that CPP-109 (Catalyst's Vigabatrin Tablets) is bioavailable and bioequivalent to Sabril(R) Tablets, the version of vigabatrin... More...>> |
| 04/04/2007 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners, Inc. Names Vice President of Pharmaceutical Development and Project Management
Steven R. Miller, Ph.D., Former Executive Director of R&D Operations at Watson Laboratories, Joins Catalyst
CORAL GABLES, Fla., April 4 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today announced the appointment of Steven R. Miller, Ph.D. as Vice President of Pharmaceutical Development... More...>> |
| 04/02/2007 | 4:30PM | PRNUS | Catalyst Pharmaceutical Partners Reports Year-End 2006 Financial Results
- Start of U.S. Phase II clinical trial for Cocaine Addiction planned for second quarter of 2007
CORAL GABLES, Fla., April 2 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today reported financial results for the year ended December 31, 2006.
"During 2006, we achieved a number of important... More...>> |
| 02/14/2007 | 10:32AM | PRNUS | Catalyst Pharmaceutical Partners, Inc. Strengthens Scientific Advisory Board With Appointment of Richard A. Rawson, Ph.D.
Dr. Rawson is an Internationally Recognized Expert on Methamphetamine Dependence
CORAL GABLES, Fla., Feb. 14 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today announced that it has appointed Dr. Richard Rawson to its Scientific Advisory Board, bringing the Board to seven members.
Dr... More...>> |
|
|
|